argenx

We're proud to share that Rebecca Michalski McLeod, U.S. General Manager, has been recognized as a Healthcare Businesswomen's Association Luminary for her dedication to patient-centricity, innovation, and driving impactful change in healthcare. Rebecca's leadership exemplifies our commitment to advancing science and transforming the lives of patients worldwide. #TogetherWeDiscover #HBAWOTY25 #HBAimpact

Living with MG or CIDP can make balancing work and daily life challenging – but you’re not alone. argenx is launching “Dare to Care” – a new webinar series focused on the real-world?challenges faced by autoimmune patients. The first session, “Balancing Energy, Work & Productivity to Thrive with Autoimmune Diseases,” will feature patient stories, expert insights, and the latest data on managing work and daily life with an autoimmune disease. ?? March 27, 2025 | ? 11:30 AM EST / 16:30 CET |??? Online ?? Register now:?https://bit.ly/4l4fC3q

In 2024, we established our Vision 2030, outlining our long-term commitment to transform the treatment of severe autoimmune diseases, and made important progress toward this goal. We’re eager to build upon this momentum in 2025 and continue advancing toward our Vision 2030 goal of reaching 50,000 patients globally. Discover more in our 2024 Annual Report:?https://bit.ly/4hoBovI #TogetherWeDiscover

Receiving an autoimmune disease diagnosis is life-changing.?While it can provide a sense of clarity and finally offer answers after what is often a long and difficult diagnosis journey, it also comes with unseen challenges. Many patients face unpredictable symptoms that disrupt daily life, along with the emotional toll of managing an often invisible condition.? ? Throughout #AutoimmuneAwarenessMonth, we’re proud to shed light on what it means to be diagnosed and live with an autoimmune disease through the stories of?patients navigating several of these complex conditions.?Discover more about our work supporting this global patient community:?https://bit.ly/42gG8ik ? #TogetherWeDiscover?

Living with an autoimmune disease means navigating challenges that aren’t always visible. It often requires making adjustments – whether it’s planning ahead, making changes to your daily routine, or finding?new ways to do the things you enjoy. This #AutoimmuneAwarenessMonth, we’re?amplifying the voices of the resilient patients who inspire our work toward a future for more options for people with autoimmune diseases. Stay tuned for more patient perspectives this month, and learn more about our commitment to the autoimmune disease community:?https://bit.ly/4bODHXv #TogetherWeDiscover

This #InternationalWomensDay, we’re celebrating our invaluable female Argonauts and highlighting how our industry can create more opportunities for #WomeninBiotech. #TogetherWeDiscover #IWD25

Today we announced that clinical trial and real-world data showcasing our focus on immunology innovation to drive autoimmune patient impact will be presented at the?American Academy of Neurology (AAN) Annual Meeting in April.? ? Learn more:?https://bit.ly/41yVRHY ? #TogetherWeDiscover #AAN2025

Advocacy starts with a single voice but is strengthened through inclusion and community. Dawn and Vanetta of the Myasthenia Gravis Holistic Society know firsthand the power of support and representation within the myasthenia gravis (MG) community. As advocates, they work to ensure that no one,?no matter their background, faces MG alone. Through outreach, support groups, and research sharing, they’re creating spaces where members of the MG community feel seen, heard, and empowered. As we close out #BlackHistoryMonth, the continued support?and work to create an inclusive future and equal care for all remains critical.?Learn more about the MG Holistic Society’s support here: https://bit.ly/4i0nSiQ #TogetherWeDiscover

Our full year and 2024 Q4 earnings report is now available. Together, we accelerated scientific discovery for patients worldwide, which included:? ? ?? Establishing commercial and clinical strategic priorities to advance Vision 2030, our goal of reaching 50,000 patients and 10 labeled indications by 2030? ? ?? Further demonstrating breadth and depth within our immunology pipeline, advancing multiple product candidates with potential across multiple high-need indications? ? ?? Continuing to invest in our Immunology Innovation Program (IIP) to drive long-term sustainable pipeline growth? ? Read more here:?https://bit.ly/4kgTLoK ? #TogetherWeDiscover?

Meet?Clive: an inspiring member of the multifocal motor neuropathy (MMN) community leading the upcoming Tour de MMN.???? ? This June, he’ll embark on a ride across France to raise MMN awareness and research funding for?GBS|CIDP Foundation International. We’re proud to join him in this incredible effort and look forward to a special ride with him next month! ? Learn more about our dedication to the MMN community: https://bit.ly/3XfNRdS ? #TogetherWeDiscover